SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item...
Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), the global...
SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item...
NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated. Hereditary hemochromatosis is a...
Email
Text